跨导管三门临床试验:不完整的数据和FDA批准的设备
Deborah Furman1, Brian Whisenant2
1Department of Internal Medicine, University of Utah, Salt Lake City, UT.
Structural heart : the journal of the Heart Team
|December 13, 2024
概括
透导管三门干预显著改善生活质量和右心室功能. 这些程序为心力衰竭患者提供了有意义的好处,具体的设备选择取决于个体患者的解剖学和风险.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 医疗器械 医疗器械
背景情况:
- 严重的三回 (TR) 显著影响心力衰竭患者的生活质量和预后.
- 通过导管三门 (TTV) 的干预为症状患者提供了一种不那么侵入性的治疗选择.
- 评估有意义的临床益处和适当的患者选择对于TTV疗法至关重要.
研究的目的:
- 评估跨导管三门干预的临床意义.
- 为了比较跨管三管边缘到边缘修复 (TEER) 和跨管三管置换 (TTVR) 的结果.
- 为了确定最佳的患者特征和不同TTV方法的选择标准.
主要方法:
- 对临床试验数据的审查,包括TRILUMINATE (TEER) 和TRISCEND II (TTVR).
- 使用堪萨斯城心肌病问卷 (KCCQ) 评估生活质量.
- 评估右心室重塑和TR减少作为关键终点.
主要成果:
- TEER和TTVR都在KCCQ得分和有利的右心室重塑方面表现出临床上有意义的改善.
- 与TRILUMINATE (TriClip TEER) (50%) 相比,TRISCEND II (EVOQUE TTVR) 的TR降低到轻度或小于轻度的比率更高 (94%).
- 风险较高的TRISCEND II人群和EVOQUE几乎消除TR与有利的死亡率趋势相关.
结论:
- 透导管三门干预措施为患有严重TR的患者提供了显著的生活质量和功能益处.
- KCCQ得分变化是TTV干预的有意义的替代终点.
- 患者的选择应考虑吸收差距的大小,心脏起器入,以及对抗凝药的耐受性,以指导TEER和TTVR之间的选择.
更多相关视频
09:57Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement
Published on: January 20, 2022
2.5K
05:31Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
2.8K
相关概念视频
01:16Clinical Trials
8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.5K
01:11Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
01:23Mitral Regurgitation II: Clinical Features and Diagnostic Tests
943
Mitral regurgitation (MR) is a valvular heart disorder in which the mitral valve fails to close tightly, allowing blood to leak backward into the heart. Understanding the clinical manifestations, assessment, diagnostic findings, and medical management of MR is crucial to effectively managing affected patients.Clinical Manifestations of Mitral RegurgitationMitral regurgitation can be acute or chronic, each presenting differently and requiring different approaches:1. Acute Mitral...
943
01:23Mitral Stenosis II: Clinical features and Diagnostic Tests
557
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
557
01:26Mitral Stenosis III: Medical Management
535
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
535